Newer Sulfonylureas Not Associated with Increased Mortality, MIs, or Strokes
Am Fam Physician. 2016 Sep 1;94(5):386.
Are newer-generation sulfonylureas associated with bad outcomes in patients with type 2 diabetes mellitus?
In multiple randomized trials, the long-term use of second- or third-generation sulfonylureas in patients with type 2 diabetes is not associated with more deaths, myocardial infarctions (MIs), or strokes. The included trials tended not to report other safety data. (Level of Evidence = 1a)
These authors reviewed two databases and the Cochrane Library to identify randomized trials of second- or third-generation sulfonylureas in patients with type 2 diabetes. Additionally, they searched for unpublished studies by looking at clinical trial registries and the abstracts of international diabetes meetings. The trials had to be at least one year in duration and evaluate all-cause or cardiovascular mortality. If reported in the included study, these authors also collected data on MIs and strokes. Because most of the trials were interested only in nearly meaningless markers of glycemic control, these outcomes were often missing (36 studies representing 10% of the patient pool), so the authors tried to contact the original study team to obtain the missing outcome data (five responded but provided no data). The authors also excluded studies that compared sulfonylureas with drugs that have been withdrawn from the market. Two of the authors independently assessed studies for inclusion and resolved disagreements by consensus, using a third party only when they could not agree. They also assessed each study's potential for bias. Finally, in addition to the usual statistical gymnastics, these authors did a “trial sequential analysis” that allows for the assessment of overall power as well as dampens the potential impact of multiple analyses.
Ultimately, they included 47 trials with approximately 38,000 patients but only 890 deaths. The trials lasted from 12 to 133 months and were generally of decent quality. In the end, the use of newer sulfonylureas was not associated with any statistically significant increase in all-cause mortality, cardiovascular mortality, MI, or stroke. When the authors restricted the analysis to studies that lasted at least two years, they found no difference. Finally, their trial sequential analysis suggested that the data are robust enough to detect at least a 0.5% absolute difference in outcomes, a value that would translate to a number needed to treat to harm of 200.
Study design: Meta-analysis (randomized controlled trial)
Funding source: Government
Setting: Various (meta-analysis)
Reference: Rados DV, Pinto LC, Remonti LR, Leitão CB, Gross JL. The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials [published correction appears in PLoS Med. 2016;13(6):e1002091]. PLoS Med. 2016;13(4):e1001992.
POEMs (patient-oriented evidence that matters) are provided by EssentialEvidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.
This series is coordinated by Sumi Sexton, MD, Associate Deputy Editor.
A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Dec 15, 2017
Access the latest issue of American Family Physician